International Tax Review is part of Legal Benchmarking Limited, 1-2 Paris Garden, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Search results for

There are 33,160 results that match your search.33,160 results
  • Hong Kong: First port of call for investors into China? The double taxation agreement (DTA) between Hong Kong and China is expected to create opportunities for Hong Kong investors. The DTA, signed on August 21 between the HKSAR government and the Central People's government will offer Hong Kong investors protection against passive income, and further enhance the jurisdiction's place as a stepping stone for investors into China.
  • The recent GlaxoSmithKline (GSK) settlement with the IRS and taxpayer's continuing problems with intangibles were two of the issues that grabbed attention at International Tax Review's sixth annual Global Transfer Pricing Forum in London
  • Welcome to the new International Tax Review! New in the sense that there's more colour and the look is fresh and different. But the magazine is not changing its aim of bringing the most up-to-date information on international tax to executives at multinational companies around the world.
  • The Australian Taxation Office (ATO) has published its second Large business and tax compliance booklet, which says that the authorities will try to complete large audits within two years.
  • Guy Kersch Guy Kersch, European head of tax for Pfizer, has left the pharmaceutical multinational to join Grant Thornton's growing transfer pricing practice.
  • Klaus Goutier The need to ensure independence of tax services from legal advice is what led the entire tax group of German law firm Goutier & Partners, to separate from the firm and merge with other professionals to form ArAnTax, a tax boutique,. "ArAnTax is a fantasy name" says partner Klaus Goutier, "it comes from the thought of art and tax".
  • The US Internal Revenue Service (IRS) and Glaxo-SmithKline's (GSK) $3.1 billion settlement marks an increased focus on transfer pricing enforcement from the IRS, and serves as a warning to taxpayers on both sides of the Atlantic. The settlement, which applies to the company's US tax returns from 1989 to 2000 is the largest ever single payment to resolve a tax dispute in the US. The IRS' original claim against GSK was for $11.5 billion for 16 years of tax accounts between 1989 and 2005.
  • Tax authorities fear they are losing millions from arbitrage. The worry means that forms of structuring which were considered legitimate are now under suspicion. International Tax Review examines an increasingly confused area of planning
  • By Alejandro Gómez Rutmann and Iván S Gutiérrez Lombardo, Deloitte
  • By Artur Braga and Carlos Romero, Ernst & Young, São Paulo